Cargando…

Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice

PURPOSE: Autologous bone grafting (BG) remains the standard reconstruction strategy for large craniofacial defects. Calcium phosphate (CaP) biomaterials, such as biphasic calcium phosphate (BCP), do not yield consistent results when used alone and must then be combined with cells through bone tissue...

Descripción completa

Detalles Bibliográficos
Autores principales: Corre, Pierre, Merceron, Christophe, Vignes, Caroline, Sourice, Sophie, Masson, Martial, Durand, Nicolas, Espitalier, Florent, Pilet, Paul, Cordonnier, Thomas, Mercier, Jacques, Remy, Séverine, Anegon, Ignacio, Weiss, Pierre, Guicheux, Jérôme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862877/
https://www.ncbi.nlm.nih.gov/pubmed/24349093
http://dx.doi.org/10.1371/journal.pone.0081599
_version_ 1782295795984236544
author Corre, Pierre
Merceron, Christophe
Vignes, Caroline
Sourice, Sophie
Masson, Martial
Durand, Nicolas
Espitalier, Florent
Pilet, Paul
Cordonnier, Thomas
Mercier, Jacques
Remy, Séverine
Anegon, Ignacio
Weiss, Pierre
Guicheux, Jérôme
author_facet Corre, Pierre
Merceron, Christophe
Vignes, Caroline
Sourice, Sophie
Masson, Martial
Durand, Nicolas
Espitalier, Florent
Pilet, Paul
Cordonnier, Thomas
Mercier, Jacques
Remy, Séverine
Anegon, Ignacio
Weiss, Pierre
Guicheux, Jérôme
author_sort Corre, Pierre
collection PubMed
description PURPOSE: Autologous bone grafting (BG) remains the standard reconstruction strategy for large craniofacial defects. Calcium phosphate (CaP) biomaterials, such as biphasic calcium phosphate (BCP), do not yield consistent results when used alone and must then be combined with cells through bone tissue engineering (BTE). In this context, total bone marrow (TBM) and bone marrow-derived mesenchymal stem cells (MSC) are the primary sources of cellular material used with biomaterials. However, several other BTE strategies exist, including the use of growth factors, various scaffolds, and MSC isolated from different tissues. Thus, clinicians might be unsure as to which method offers patients the most benefit. For this reason, the aim of this study was to compare eight clinically relevant BTE methods in an “all-in-one” study. METHODS: We used a transgenic rat strain expressing green fluorescent protein (GFP), from which BG, TBM, and MSC were harvested. Progenitor cells were then mixed with CaP materials and implanted subcutaneously into nude mice. After eight weeks, bone formation was evaluated by histology and scanning electron microscopy, and GFP-expressing cells were tracked with photon fluorescence microscopy. RESULTS/CONCLUSIONS: Bone formation was observed in only four groups. These included CaP materials mixed with BG or TBM, in which abundant de novo bone was formed, and BCP mixed with committed cells grown in two- and three-dimensions, which yielded limited bone formation. Fluorescence microscopy revealed that only the TBM and BG groups were positive for GFP expressing-cells, suggesting that these donor cells were still present in the host and contributed to the formation of bone. Since the TBM-based procedure does not require bone harvest or cell culture techniques, but provides abundant de novo bone formation, we recommend consideration of this strategy for clinical applications.
format Online
Article
Text
id pubmed-3862877
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-38628772013-12-17 Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice Corre, Pierre Merceron, Christophe Vignes, Caroline Sourice, Sophie Masson, Martial Durand, Nicolas Espitalier, Florent Pilet, Paul Cordonnier, Thomas Mercier, Jacques Remy, Séverine Anegon, Ignacio Weiss, Pierre Guicheux, Jérôme PLoS One Research Article PURPOSE: Autologous bone grafting (BG) remains the standard reconstruction strategy for large craniofacial defects. Calcium phosphate (CaP) biomaterials, such as biphasic calcium phosphate (BCP), do not yield consistent results when used alone and must then be combined with cells through bone tissue engineering (BTE). In this context, total bone marrow (TBM) and bone marrow-derived mesenchymal stem cells (MSC) are the primary sources of cellular material used with biomaterials. However, several other BTE strategies exist, including the use of growth factors, various scaffolds, and MSC isolated from different tissues. Thus, clinicians might be unsure as to which method offers patients the most benefit. For this reason, the aim of this study was to compare eight clinically relevant BTE methods in an “all-in-one” study. METHODS: We used a transgenic rat strain expressing green fluorescent protein (GFP), from which BG, TBM, and MSC were harvested. Progenitor cells were then mixed with CaP materials and implanted subcutaneously into nude mice. After eight weeks, bone formation was evaluated by histology and scanning electron microscopy, and GFP-expressing cells were tracked with photon fluorescence microscopy. RESULTS/CONCLUSIONS: Bone formation was observed in only four groups. These included CaP materials mixed with BG or TBM, in which abundant de novo bone was formed, and BCP mixed with committed cells grown in two- and three-dimensions, which yielded limited bone formation. Fluorescence microscopy revealed that only the TBM and BG groups were positive for GFP expressing-cells, suggesting that these donor cells were still present in the host and contributed to the formation of bone. Since the TBM-based procedure does not require bone harvest or cell culture techniques, but provides abundant de novo bone formation, we recommend consideration of this strategy for clinical applications. Public Library of Science 2013-12-11 /pmc/articles/PMC3862877/ /pubmed/24349093 http://dx.doi.org/10.1371/journal.pone.0081599 Text en © 2013 Corre et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Corre, Pierre
Merceron, Christophe
Vignes, Caroline
Sourice, Sophie
Masson, Martial
Durand, Nicolas
Espitalier, Florent
Pilet, Paul
Cordonnier, Thomas
Mercier, Jacques
Remy, Séverine
Anegon, Ignacio
Weiss, Pierre
Guicheux, Jérôme
Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice
title Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice
title_full Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice
title_fullStr Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice
title_full_unstemmed Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice
title_short Determining a Clinically Relevant Strategy for Bone Tissue Engineering: An “All-in-One” Study in Nude Mice
title_sort determining a clinically relevant strategy for bone tissue engineering: an “all-in-one” study in nude mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3862877/
https://www.ncbi.nlm.nih.gov/pubmed/24349093
http://dx.doi.org/10.1371/journal.pone.0081599
work_keys_str_mv AT correpierre determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT merceronchristophe determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT vignescaroline determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT souricesophie determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT massonmartial determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT durandnicolas determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT espitalierflorent determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT piletpaul determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT cordonnierthomas determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT mercierjacques determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT remyseverine determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT anegonignacio determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT weisspierre determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice
AT guicheuxjerome determiningaclinicallyrelevantstrategyforbonetissueengineeringanallinonestudyinnudemice